Corvus Pharmaceuticals CRVS Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's additional paid-in capital?
- Corvus Pharmaceuticals (CRVS) reported additional paid-in capital of $667.78M in Q1 2026.
- How has Corvus Pharmaceuticals's additional paid-in capital changed year-over-year?
- Corvus Pharmaceuticals's additional paid-in capital increased by 54.4% year-over-year, from $432.39M to $667.78M.
- What is the long-term trend for Corvus Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's additional paid-in capital has grown at a 9.9% compound annual growth rate (CAGR), from $295.28M to $474.39M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.